.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
US Department of Justice
Covington
QuintilesIMS
McKinsey
Farmers Insurance
Merck
Colorcon
Mallinckrodt
Julphar

Generated: December 13, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,140,329

« Back to Dashboard

Which drugs does patent 6,140,329 protect, and when does it expire?


Patent 6,140,329 protects CIALIS and is included in one NDA. There have been two Paragraph IV challenges on Cialis.

This patent has one hundred and thirty-seven patent family members in forty-nine countries.

Summary for Patent: 6,140,329

Title: Use of cGMP-phosphodiesterase inhibitors in methods and compositions to treat impotence
Abstract:The use of (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-p yrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione, (3S 6R,12aR)-2,3,6,7,12,12a-hexahydro-2,3-dimethyl-6-(3,4-methylenedioxyhenyl) -pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione, and physiologically acceptable salts and solvates thereof, in methods and compositions for the treatment of impotence.
Inventor(s): Daugan; Alain Claude-Marie (Les Ulis, FR)
Assignee: ICOS Corporation (Bothell, WA)
Application Number:08/981,989
Patent Claim Types:
see list of patent claims
Use; Composition; Process; Formulation; Delivery;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
LillyCIALIStadalafilTABLET;ORAL021368-004Jan 7, 2008RXYesNo► Subscribe► Subscribe► SubscribeYTREATMENT OF ERECTILE DYSFUNCTION
LillyCIALIStadalafilTABLET;ORAL021368-001Nov 21, 2003RXYesNo► Subscribe► Subscribe► SubscribeYTREATMENT OF ERECTILE DYSFUNCTION
LillyCIALIStadalafilTABLET;ORAL021368-001Nov 21, 2003RXYesNo► Subscribe► Subscribe► SubscribeYTREATMENT OF ERECTILE DYSFUNCTION AND THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA
LillyCIALIStadalafilTABLET;ORAL021368-002Nov 21, 2003RXYesNo► Subscribe► Subscribe► SubscribeYTREATMENT OF ERECTILE DYSFUNCTION
LillyCIALIStadalafilTABLET;ORAL021368-003Nov 21, 2003RXYesYes► Subscribe► Subscribe► SubscribeYTREATMENT OF ERECTILE DYSFUNCTION
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,140,329

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9514464Jul 14, 1995
PCT Information
PCT FiledJuly 11, 1996PCT Application Number:PCT/EP96/03024
PCT Publication Date:February 06, 1997PCT Publication Number: WO97/03675

Non-Orange Book Patents for Patent: 6,140,329

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,608,065 Use of cGMP phosphodiesterase inhibitors in methods to treat female sexual dysfunction► Subscribe
5,859,006 Tetracyclic derivatives; process of preparation and use► Subscribe
6,784,179 Tetracyclic derivatives, process of preparation and use► Subscribe
6,369,059 Tetracyclic derivatives, process of preparation and use► Subscribe
6,127,542 Tetracyclic derivatives, process of preparation and use► Subscribe
6,143,746 Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use► Subscribe
6,025,494 Tetracyclic derivatives, process of preparation and use► Subscribe
5,981,527 Cyclic GMP-specific phosphodiesterase inhibitors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,140,329

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO)556► Subscribe
African Regional IP Organization (ARIPO)9500712► Subscribe
Argentina003455► Subscribe
Austria169018► Subscribe
Austria216997► Subscribe
Austria327756► Subscribe
Australia1574895► Subscribe
Australia5785699► Subscribe
Australia6419196► Subscribe
Australia6419296► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Baxter
Chinese Patent Office
Colorcon
UBS
Chubb
Novartis
Cipla
Johnson and Johnson
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot